Top Page
Shanghai Henlius Biotech, Inc. Class H
(2696)
Shanghai Henlius Biotech, Inc. Class H (2696) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai Henlius Biotech, Inc. Class H Business Overview & Revenue Model
Shanghai Henlius Biotech, Inc. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.80B | 5.72B | 5.39B | 3.21B | 1.68B | 587.59M |
| Gross Profit | 4.39B | 4.18B | 3.92B | 2.37B | 1.16B | 405.47M |
| EBITDA | 1.14B | 1.15B | 911.33M | -310.61M | -671.74M | -814.06M |
| Net Income | 824.30M | 820.47M | 546.02M | -695.26M | -984.05M | -993.54M |
Balance Sheet | ||||||
| Total Assets | 11.55B | 10.60B | 9.90B | 8.92B | 7.17B | 6.44B |
| Cash, Cash Equivalents and Short-Term Investments | 972.50M | 772.96M | 1.01B | 680.48M | 742.32M | 1.11B |
| Total Debt | 3.67B | 3.65B | 4.09B | 3.68B | 2.62B | 1.83B |
| Total Liabilities | 8.14B | 7.58B | 7.71B | 7.29B | 4.88B | 3.24B |
| Stockholders Equity | 3.41B | 3.01B | 2.19B | 1.64B | 2.30B | 3.20B |
Cash Flow | ||||||
| Free Cash Flow | 930.30M | 404.68M | 36.48M | -383.67M | -1.04B | -2.12B |
| Operating Cash Flow | 990.62M | 1.24B | 1.05B | 981.62M | 90.39M | -609.58M |
| Investing Cash Flow | -123.16M | -909.97M | -1.00B | -1.36B | -1.68B | -1.51B |
| Financing Cash Flow | 0.00 | -643.37M | 144.43M | 858.02M | 648.30M | 995.79M |
Shanghai Henlius Biotech, Inc. Class H Technical Analysis
Shanghai Henlius Biotech, Inc. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$34.13B | 38.35 | 27.37% | ― | 2.57% | 18.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$24.44B | -16.84 | -161.12% | ― | -56.94% | -190.36% | |
43 Neutral | HK$38.97B | -23.90 | -15.06% | ― | 39.02% | 48.26% | |
40 Neutral | HK$21.75B | -11.37 | -30.41% | ― | 23.87% | 30.08% | |
40 Underperform | HK$21.45B | -111.85 | -3.06% | ― | 68.75% | 55.64% |
Shanghai Henlius Biotech, Inc. Class H Corporate Events
Shanghai Henlius Biotech, Inc. announced that its subsidiary, Henlius USA Inc., has received Orphan-drug Designation from the U.S. FDA for HLX43, an anti-PD-L1 antibody-drug conjugate, for the treatment of thymic epithelial tumors. This designation provides the company with benefits such as tax credits, fee exemptions, and market exclusivity, which could enhance its competitive positioning in the oncology market, particularly in the U.S., where no similar PD-L1 targeting ADCs have been approved.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$77.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced that its phase 3 clinical study of HANSIZHUANG (serplulimab injection) in combination with chemotherapy for the treatment of early-stage gastric cancer met its primary endpoint of event-free survival. This significant finding supports an early new drug application submission, indicating a promising advancement in cancer treatment. The study demonstrated a notable improvement in the pathological complete response rate and a reduction in recurrence risk, with a favorable safety profile, enhancing the company’s position in the oncology market.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$79.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced the approval of its phase 1b/2 clinical trial application for HLX43, an anti-PD-L1 antibody-drug conjugate, in combination with HLX07 for treating advanced/metastatic solid tumors. This approval by the National Medical Products Administration marks a significant step in the company’s clinical development efforts, potentially enhancing its market position in oncology therapeutics. The trial’s previous data demonstrated promising results, showing high response rates and good safety profiles, especially in patients with advanced non-small cell lung cancer, indicating a positive outlook for stakeholders.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced that its investigational new drug application for HLX13, a biosimilar of Ipilimumab, was approved by the FDA for a phase 1 clinical trial as a first-line treatment for unresectable hepatocellular carcinoma. This approval marks a significant step for the company in expanding its clinical trials internationally, potentially enhancing its market position in the oncology sector and providing new treatment options for various cancers.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has initiated an international multi-center phase 1 clinical trial for HLX17, a biosimilar of pembrolizumab, in patients with multiple resected solid tumors in mainland China. This trial aims to evaluate the pharmacokinetic profile, efficacy, safety, and immunogenicity of HLX17 compared to KEYTRUDA, with plans to expand the trial to the United States, Europe, and Australia. The announcement marks a significant step in the company’s efforts to position itself in the global oncology market, leveraging the high global sales of pembrolizumab, which reached approximately USD 32.056 billion in 2024.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced that the European Commission has approved the marketing authorization applications for two of its products, BILDYOS® and BILPREVDA®, for the treatment of osteoporosis and other bone-related conditions in the EU and EEA countries. This approval is based on extensive comparative studies demonstrating the similarity of HLX14 to the reference product, Prolia®, and marks a significant step in the company’s global expansion strategy, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in Australia in its international multicentre phase 2 clinical study of HLX43, an anti-PD-L1 antibody-drug conjugate, for advanced non-small cell lung cancer (NSCLC). The study, also ongoing in mainland China and the United States, aims to evaluate the efficacy and safety of HLX43. Previous phase 1 results demonstrated promising response rates and safety profiles, particularly in patients with advanced tumors who have not responded to other treatments, indicating potential significant impact on the company’s market positioning in oncology therapeutics.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced that the U.S. FDA has approved the investigational new drug application for HLX17, a biosimilar of pembrolizumab, for phase 1 clinical trials. This approval marks a significant step for the company as it aims to conduct international multi-center trials, potentially enhancing its position in the oncology market, where pembrolizumab sales reached approximately USD 32.056 billion in 2024.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced that the U.S. FDA has approved two of its biosimilar products, BILDYOS® and BILPREVDA®, for eight indications related to osteoporosis and other bone conditions. This approval is based on comprehensive studies demonstrating the biosimilars’ similarity to the reference products in terms of quality, safety, and efficacy. The approval is expected to enhance the company’s market position and expand its global reach, particularly through its partnership with Organon LLC for commercialization outside of China.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced the results of its 2025 third extraordinary general meeting, where key resolutions regarding the re-appointment of board members and executives were approved. The re-appointments include the chairman of the board, chairman of the board of supervisors, and the chief executive officer, which are expected to provide continuity in leadership and strategic direction for the company.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced the composition of its board of directors and their respective roles within the company. This announcement provides clarity on the leadership structure, which may impact the company’s strategic direction and governance, potentially influencing stakeholder confidence and market positioning.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced the granting of 67,500 options and 87,500 restricted stock units (RSUs) to selected participants under its Share Option and RSU Schemes. This strategic move aims to align employee incentives with the company’s performance goals, potentially enhancing its market position and operational efficiency. The vesting of these options is tied to specific performance targets, including financial and R&D indicators, as well as market capitalization objectives, reflecting the company’s commitment to driving growth and value for its stakeholders.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. reported a modest increase in total revenue and profit for the first half of 2025, driven by drug sales, R&D services, and license income. The company’s international strategy has led to significant growth in overseas product sales, particularly in the United States, enhancing its global profitability. The company has successfully expanded its product approvals across multiple countries, with notable achievements in the marketing of its anti-PD-1 monoclonal antibody, HANSIZHUANG, and the biosimilar HANQUYOU. Strategic licensing agreements further bolster its international commercial footprint.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$77.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced the dosing of the first patient in the United States for its international multi-center phase 2 clinical study of HLX43, targeting advanced non-small cell lung cancer. This study, which is also ongoing in China, aims to assess the efficacy and safety of HLX43, with plans to expand trials to Australia, Japan, and other countries. The announcement marks a significant step in the company’s efforts to advance its oncology pipeline and strengthen its position in the global biotechnology market.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$77.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has issued a clarification announcement regarding the closure of its register of members, specifying the requirements for lodging transfer documents and share certificates for registration by August 26, 2025. This announcement ensures that shareholders are informed of the necessary procedures, potentially impacting shareholder transactions and company operations.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced that its New Drug Application for HLX04-O, a recombinant anti-VEGF humanized monoclonal antibody injection for treating wet age-related macular degeneration (wAMD), has been accepted by China’s National Medical Products Administration. This development is significant as it marks a step forward in the company’s efforts to provide new treatment options for wAMD, a condition with limited approved treatments in China. The acceptance of the NDA follows successful clinical trials demonstrating the drug’s non-inferiority to existing treatments and its favorable safety profile, potentially positioning Henlius as a key player in the ophthalmic drug market.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced an extraordinary general meeting to be held on August 29, 2025, to discuss and approve several resolutions. These include the re-appointment and appointment of directors and shareholder representative supervisors, as well as proposed amendments to the Rules of Procedures for the General Meeting, the Board, and the Board of Supervisors. The meeting’s outcomes could impact the company’s governance structure and operational procedures, potentially influencing its strategic direction and stakeholder engagement.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced the proposed re-appointment and appointment of directors and supervisors for the fourth session of its board. This includes the re-appointment of several current directors and the introduction of new members, reflecting the company’s strategic focus on maintaining a robust governance structure. The decisions are set to be approved at the upcoming Extraordinary General Meeting (EGM), which underscores the company’s commitment to strong leadership and oversight, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced that its anti-PD-L1 antibody-drug conjugate, HLX43, has received approval from the U.S. FDA to begin a phase 1 clinical trial for the treatment of thymic carcinoma. This approval marks a significant step in the company’s efforts to advance its oncology pipeline, with plans to conduct further clinical studies in multiple countries. The approval positions Henlius as a key player in the ADC market, particularly as no ADC targeting PD-L1 has been approved globally yet, potentially enhancing its market presence and offering new treatment options for patients with advanced cancers.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced the commencement of a Phase 2 clinical study for HLX79, a human sialidase fusion protein, in combination with HANLIKANG, for treating active glomerulonephritis in Mainland China. This study aims to evaluate the safety, tolerability, and efficacy of the combination treatment, potentially enhancing B lymphocyte depletion and benefiting patients with autoimmune diseases. The development of HLX79 is part of a global collaboration with Palleon Pharmaceuticals, with Shanghai Henlius holding exclusive rights in China.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.